Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer | Eli Lilly and Company - investor.lilly.com

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer | Eli Lilly and Company    investor.lilly.com Selpercatinib Cuts Recurrence Risk in Early RET+ NSCLC    Medscape ASCO26: Lilly details "practice changing" data for RET inhibitor in earlier stage lung cancer    FirstWord Pharma ASCO: Lilly's Retevmo aces early-stage lung cancer trial    pharmaphorum ASCO: Lilly ties Retevmo to ‘dramatic’ outcomes in early-stage lung cancer with rare RET biomarker    Fierce Pharma

Original source: Google News